Clinical Trials Logo

Clinical Trial Summary

The Objectives of this study are:

1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional maturation when administered during the maturation process compared with placebo.

2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary procedures to aid in fistula maturation compared with placebo.

3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for hemodialysis compared with placebo.

This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).


Clinical Trial Description

Objectives:

1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional maturation when administered during the maturation process compared with placebo.

2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary procedures to aid in fistula maturation compared with placebo.

3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for hemodialysis compared with placebo.

This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).

Participation in this study will not affect standard care of patients with AV fistulae receiving hemodialysis. The only additional treatment is administration of the study drug or placebo and additional monitoring, including one additional ultrasound, for 6 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02475837
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 2
Start date August 26, 2015
Completion date October 23, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05462223 - Alucent Vessel Restoration System for AVF N/A
Completed NCT02363972 - Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD N/A
Terminated NCT04626427 - The WavelinQâ„¢ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation N/A
Completed NCT01471041 - Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae Phase 2/Phase 3
Not yet recruiting NCT05569109 - av Fistula Patency Loss as a Cause of Fistula Failure and Hyperphosphatemia
Active, not recruiting NCT04484220 - Ellipsys Vascular Access System Post Market Surveillance (PS) Study N/A
Active, not recruiting NCT04327609 - SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications N/A